Unconfigured Ad

Collapse

Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc

Forums Topics Posts Last Post
No forums found.
  •  
  • Time
  • Answered
  • Show
  • New Topics
Clear All
new posts
There are no conversations in this channel.
 
  • Time
  • Show
Clear All
new posts
Please log in to your account to view your subscribed posts.
  •  
  • Time
  • Answered
  • Show
  • Sort By
  • Order
Clear All
new posts
Topics Statistics Last Post
Started by laura, 05-09-2011, 04:42 AM
35 responses
107,959 views
0 reactions
Last Post laura
by laura
 
Started by sci_guy, 01-23-2008, 11:19 PM
236 responses
688,036 views
1 reaction
Last Post ECO
by ECO
 
Started by gwilymh, 09-24-2014, 03:19 PM
4 responses
3,638 views
0 reactions
Last Post GenoMax
by GenoMax
 
Started by arkilis, 10-02-2014, 07:40 PM
3 responses
5,616 views
0 reactions
Last Post GenoMax
by GenoMax
 
Started by dmb107, 10-06-2014, 02:31 PM
0 responses
2,564 views
0 reactions
Last Post dmb107
by dmb107
 
Started by BBroadley, 04-23-2014, 12:49 AM
0 responses
3,415 views
0 reactions
Last Post yutakajr  
Started by morning latte, 10-06-2014, 10:41 AM
0 responses
1,050 views
0 reactions
Last Post morning latte  
Started by LeonDK, 10-05-2014, 10:57 PM
2 responses
1,336 views
0 reactions
Last Post Brian Bushnell  
Started by spaceace507, 10-06-2014, 07:29 AM
0 responses
3,402 views
0 reactions
Last Post spaceace507  
Started by akshaya.ramesh, 10-06-2014, 06:46 AM
0 responses
1,127 views
0 reactions
Last Post akshaya.ramesh  
Started by SylvainL, 09-29-2014, 06:04 AM
23 responses
3,426 views
0 reactions
Last Post mbblack
by mbblack
 
Started by Gonza, 10-06-2014, 04:38 AM
0 responses
1,616 views
0 reactions
Last Post Gonza
by Gonza
 
No topics found.
  • Time
Clear All
No photos found.
  • Time
Clear All

Webinars

Collapse

Recent Articles

Collapse

  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    Today, 10:25 AM
  • SEQadmin2
    How Immunogenomics Decodes Immunity’s Genetic Blueprint
    by SEQadmin2




    The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.

    This convergence of genetics, immunology, and computation...
    09-01-2026, 05:41 AM
  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 09-25-2026, 09:06 AM
0 responses
27 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 09-23-2026, 11:05 AM
0 responses
24 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 09-18-2026, 11:37 AM
1 response
45 views
0 reactions
Last Post pekgio
by pekgio
 
Working...